WallStSmart
SBFM

Sunshine Biopharma Inc

NASDAQ: SBFM · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$1.03
-3.38% today

Updated 2026-06-04

Market cap
$4.33M
P/E ratio
P/S ratio
0.12x
EPS (TTM)
$-12.50
Dividend yield
52W range
$2 – $24
Volume
16.8M

Sunshine Biopharma Inc (SBFM) Financial statements

SEC filings — annual and quarterly data.

Profit margin
-16.46%
Operating margin
-12.34%
ROE
-27.30%
ROA
-10.00%
Debt/equity
0.03x

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2007$-13122.00
2008$-31105.00
2009$-25015.00
2010$-537382.00
2011$-556202.00
2012$-707952.00
2013$0.00$-2.49M
2014$0.00$-1.93M
2015$1708.00$-1.65M100.00%-45,683.67%-96,774.47%
2016$0.00$-3.50M
2017$0.00$-1.04M
2018$447200.00$-2.16M12.55%-260.85%-482.15%
2019$21121.00$-1.66M47.68%-3,037.91%-7,860.85%
2020$71410.00$-2.78M63.80%-807.83%-3,898.74%
2021$228426.00$-12.44M48.42%-1,068.24%-5,444.41%
2022$4.35M$-26.74M39.04%-199.60%-615.44%
2023$24.09M$-4.51M34.61%-19.86%-18.70%
2024$34.87M$-5.13M30.60%-16.67%-14.72%
2025$36.31M$-5.98M32.84%-12.34%-16.46%

Frequently asked questions

What is Sunshine Biopharma Inc's revenue?

Sunshine Biopharma Inc's trailing twelve-month revenue is $35.49M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is SBFM?

In its most recent fiscal year, SBFM ran a gross margin of 32.84%, an operating margin of -12.34%, and a net margin of -16.46%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does SBFM generate?

SBFM produced $-5.51M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is SBFM's balance sheet healthy?

SBFM holds $9.12M in cash and equivalents against — in long-term debt, on $23.04M of shareholder equity. That debt is best read against the cash flow the business throws off each year.